Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 ( VKORC1) affects gene expression and warfarin dose requirement

Blood

Volumn 112, Issue 4, 2008, Pages 1013-1021

  Wang, Danxin ^a,b   Chen, Huizi ^a,b   Momary, Kathryn M ^c   Cavallari, Larisa H ^c   Johnson, Julie A ^d   Sadée, Wolfgang ^a,e  

^a Program in Pharmacogenetics   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^d UNIVERSITY OF FLORIDA HEALTH   (United States)

^e OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; OXIDOREDUCTASE; UNCLASSIFIED DRUG; VKORC1 ENZYME; WARFARIN; MENADIONE EPOXIDASE; MIXED FUNCTION OXIDASE; PROTEIN SUBUNIT;

ALLELE; ARTICLE; CHROMATIN; CONTROLLED STUDY; DNA POLYMORPHISM; GENE EXPRESSION; HAPLOTYPE; HUMAN; HUMAN TISSUE; IMMUNOPRECIPITATION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REPORTER GENE; ANTIBODY SPECIFICITY; BIOPSY; CAUCASIAN; CELL CULTURE; CLINICAL TRIAL; ENZYMOLOGY; ETHNIC GROUP; GENE EXPRESSION REGULATION; GENETICS; LIVER; NEGRO; PHARMACOGENETICS; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM;

AFRICAN CONTINENTAL ANCESTRY GROUP; BIOPSY; CELLS, CULTURED; CHROMATIN; ETHNIC GROUPS; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENE EXPRESSION REGULATION; HUMANS; LIVER; MIXED FUNCTION OXYGENASES; ORGAN SPECIFICITY; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS (GENETICS); PROTEIN SUBUNITS; RNA, MESSENGER; WARFARIN;

EID: 51649084617     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-03-144899     Document Type: Article

References (48)

1. Oldenburg J, Bevans CG, Muller CR, Watzka M. Vitamin K epoxide reductase complex subunit 1 (VKORC1): the key protein of the vitamin K cycle. Antioxid Redox Signal. 2006;8:347-353.
2. Berkner KL, Runge KW. The physiology of vitamin K nutriture and vitamin K-dependent protein function in atherosclerosis. J Thromb Haemost. 2004;2:2118-2132.
3. Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(suppl):204-233.
4. Rost S, Fregin A, Ivaskevicius V, et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature. 2004;427:537-541.
5. Li T, Chang CY, Jin DY, Lin PJ, Khvorova A, Stafford DW. Identification of the gene for vitamin K epoxide reductase. Nature. 2004;427:541-544.
6. Sconce EA, Khan TI, Wynne HA, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood. 2005;106:2329-2333.
7. Yuan HY, Chen JJ, Lee MT, et al. Anovel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum Mol Genet. 2005;14:1745-1751.
8. Wadelius M, Chen LY, Downes K, et al. Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J. 2005; 5:262-270.
9. Bodin L, Verstuyft C, Tregouet DA, et al. Cyto- chrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood. 2005;106:135-140.
10. D'Andrea G, D'Ambrosio RL, Di Perna P, et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose- anticoagulant effect of warfarin. Blood. 2005;105:645-649.
11. Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med. 2005;352: 2285-2293.
12. Rettie AE, Tai G. The pharmocogenomics of warfarin: closing in on personalized medicine. Mol Interv. 2006;6:223-227.
13. Aquilante CL, Langaee TY, Lopez LM, et al. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Clin Pharmacol Ther. 2006;79:291-302.
14. National Center for Biotechnology Information. Entrez SNP. http://www.ncbi.nlm.nih.gov/sites/entrez?db=snp. Accessed May, 2006.
15. Schwarz UI, Ritchie MD, Bradford Y, et al. Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med. 2008;358: 999-1008.
16. Wen MS, Lee M, Chen JJ, et al. Prospective study of warfarin dosage requirements based on CYP2C9 and VKORC1 genotypes. Clin Pharmacol Ther. 2008;84:83-89.
17. Montes R, Ruiz de Gaona E, Martinez-Gonzalez MA, Alberca I, Hermida J. The c.-1639G>A polymorphism of the VKORC1 gene is a major determinant of the response to acenocoumarol in anti-coagulated patients. Br J Haematol. 2006;133:183-187.
18. Schalekamp T, Brasse BP, Roijers JF, et al. VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation. Clin Pharmacol Ther. 2006;80:13-22.
19. Tham LS, Goh BC, Nafziger A, et al. Awarfarin- dosing model in Asians that uses single-nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9. Clin Pharmacol Ther. 2006;80:346-355.
20. Caldwell MD, Berg RL, Zhang KQ, et al. Evaluation of genetic factors for warfarin dose prediction. Clin Med Res. 2007;5:8-16.
21. Larramendy-Gozalo C, Yang JQ, Verstuyft C, et al. Genetic polymorphism of vitamin K epoxide reductase (VKORC1) 1173C>T in a Chinese and a Caucasian population. Basic Clin Pharmacol Toxicol. 2006;98:611-613.
22. Marsh S, King CR, Porche-Sorbet RM, Scott- Horton TJ, Eby CS. Population variation in VKORC1 haplotype structure. J Thromb Haemost. 2006;4:473-474.
23. Lee SC, Ng SS, Oldenburg J, et al. Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population. Clin Pharmacol Ther. 2006;79:197-205.
24. International HapMap Project. HapMap. http:// www.hapmap.org. Accessed 2007.
25. Cirulli ET, Goldstein DB. In vitro assays fail to predict in vivo effects of regulatory polymorphisms. Hum Mol Genet. 2007;16:1931-1939.
26. Momary KM, Shapiro NL, Viana MA, Nutescu EA, Helgason CM, Cavallari LH. Factors influencing warfarin dose requirements in African-Americans. Pharmacogenomics. 2007;8:1535-1544.
27. Pinsonneault J, Nielsen CU, Sadee W. Genetic variants of the human H +/dipeptide transporter PEPT2: analysis of haplotype functions. J Pharmacol Exp Ther. 2004;311:1088-1096.
28. Wang D, Johnson AD, Papp AC, Kroetz DL, Sadee W. Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenet Genomics. 2005;15:693-704.
29. Wang D, Papp AC, Binkley PF, Johnson JA, Sadee W. Highly variable mRNA expression and splicing of L-type voltage-dependent calcium channel alpha subunit 1C in human heart tissues. Pharmacogenet Genomics. 2006;16:735-745.
30. Kaminsky ZA, Assadzadeh A, Flanagan J, Petronis A. Single nucleotide extension technology for quantitative site-specific evaluation of metC/C in GC-rich regions. Nucleic Acids Res. 2005;33:e95.
31. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA. 1996;93:9821-9826.
32. Huang HS, Matevossian A, Jiang Y, Akbarian S. Chromatin immunoprecipitation in postmortem brain. J Neurosci Methods. 2006;156:284-292.
33. Zhang Y, Bertolino A, Fazio L, et al. Polymorphisms in human dopamine D2 receptor gene affect gene expression, splicing and neuronal activity during working memory. Proc Natl Acad Sci USA. 2007;104:20552-20557.
34. Jenuwein T, Allis CD. Translating the histone code. Science. 2001;293:1074-1080.
35. Massari ME, Murre C. Helix-loop-helix proteins: regulators of transcription in eucaryotic organisms. Mol Cell Biol. 2000;20:429-440.
36. Plass C, Soloway PD. DNA methylation, imprinting and cancer. Eur J Hum Genet. 2002;10:6-16.
37. Jones PA, Takai D. The role of DNAmethylation in mammalian epigenetics. Science. 2001;293:1068-1070.
38. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 2003;349:2042-2054.
39. Kimura R, Miyashita K, Kokubo Y, et al. Genotypes of vitamin K epoxide reductase, gamma- glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients. Thromb Res. 2007;120:181-186.
40. Dang MT, Hambleton J, Kayser SR. The influence of ethnicity on warfarin dosage requirement. Ann Pharmacother. 2005;39:1008-1012.
41. Wang Y, Zhang W, Zhang Y, et al. VKORC1 haplotypes are associated with arterial vascular diseases (stroke, coronary heart disease, and aortic dissection). Circulation. 2006;113:1615-1621.
42. Teichert M, Visser LE, van Schaik RH, et al. Vitamin K epoxide reductase complex subunit 1 (VKORC1) polymorphism and aortic calcification: the Rotterdam Study. Arterioscler Thromb Vasc Biol. 2008;28:771-776.
43. Watzka M, Nebel A, El Mokhtari NE, et al. Functional promoter polymorphism in the VKORC1 gene is no major genetic determinant for coronary heart disease in Northern Germans. Thromb Haemost. 2007;97:998-1002.
44. Alland L, Muhle R, Hou H Jr, et al. Role for N-CoR and histone deacetylase in Sin3-mediated transcriptional repression. Nature. 1997;387:49-55.
45. Bu Y, Gelman IH. v-Src-mediated down-regulation of SSeCKS metastasis suppressor gene promoter by the recruitment of HDAC1 into a USF1-Sp1-Sp3 complex. J Biol Chem. 2007;282:26725-26739.
46. Kouzarides T. Chromatin modifications and their function. Cell. 2007;128:693-705.
47. Nightingale KP, Gendreizig S, White DA, Bradbury C, Hollfelder F, Turner BM. Cross-talk between histone modifications in response to his- tone deacetylase inhibitors: MLL4 links histone H3 acetylation and histone H3K4 methylation. J Biol Chem. 2007;282:4408-4416.
48. Kato M, Zhang J, Wang M, et al. MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-beta-induced collagen expression via inhibition of E-box repressors. Proc Natl Acad Sci U S A. 2007;104:3432-3437.